Journal profile · Pharmacology & Pharmacy
Drug Development and Industrial Pharmacy
ISSN 0363-9045 · eISSN 1520-5762 · Informa Healthcare · UNITED STATES · Monthly
Drug Development and Industrial Pharmacy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.56; subscription journal; APC charged, amount not published; median 110 days to acceptance (102 articles, last 24 months); community-reported acceptance: about 75%; 167 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Drug Development and Industrial Pharmacy is published by Informa Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug Solubulity and Delivery Systems, Advanced Drug Delivery Systems and Advancements in Transdermal Drug Delivery, together about 49.2% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
Drug Development and Industrial Pharmacy is a subscription-based journal publishing novel, original, peer-reviewed research and review manuscripts related to pharmaceutical science research, specifically in the fields of nanomedicines, formulation, development and delivery technologies, biopharmaceuticals, new material development, processing technology advancement, and preclinical, clinical and regulatory evaluation of formulation and delivery technologies. Research papers must be hypothesis driven and emphasize innovative breakthrough topics. Timely critical review papers within the journal scope are also welcomed, alongside data notes, letters to the editor, rapid communications and method articles. The priority topics for the journal include: i. Nanomedicines ii. New Material Development iii. Advanced Formulation, Development and Delivery Technologies iv. Innovative Processing and Analytical Technologies v. Preclinical and Clinical Evaluation of Formulation Technologies vi. Regulatory Aspects The journal’s audience includes pharmacists, academic and industry scientists (working in the areas of pharmaceutical science, material science, biopharmaceuticals, nanomedicine, pharmaceutical technology), regulatory scientists, pharmacologists, toxicologists, clinicians, medicinal chemists or chemists working in area of designing and developing new materials (i.e. polymers, lipids, excipients), and analytical chemists. All articles received by the journal will be subject to single-anonymous peer review. Authors can choose to publish gold open access in this journal. Read the Instructions for Authors for information on how to submit your article.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Imran SaleemPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United States 17, United Kingdom 3, Italy 3, Egypt 3, Chile 2 (42 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics24.5%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics15.8%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics9%
- Analytical Methods in PharmaceuticalsChemistry8.1%
- Analytical Chemistry and ChromatographyChemistry5.1%
- Crystallization and Solubility StudiesMaterials Science4.9%
- Pharmaceutical studies and practicesMedicine3.8%
- Nanoparticle-Based Drug DeliveryMaterials Science3.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Chemistry, Medicinal | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Chemistry, Medicinal | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Chemistry, Medicinal | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCASPublisher website
Other: Biomedical Reference Collection: Comprehensive, Biotechnology Abstracts, Derwent Chimera, Derwent Drug File, ETOH, International Pharmaceutical Abstracts, Journal Citation Reports/Science Edition, PASCAL, PopLine, SciSearch, SIIC CABI Databases: Global Health, Abstracts on Hygiene and Communicable Diseases, Agricultural Economics Database, Dairy Science Abstracts, Environmental Science Database, Nutrition Abstracts and Reviews Series A, Nutrition and Food Sciences Database, NutritionCD, Parasitology Database, Plant Protection Database, Protozoological Abstracts, Review of Aromatic and Medicinal Plants, Review of Medical and Veterinary Mycology, Rural Development Abstracts, Soil Science Database
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.56LetPub ·
- Impact factor (publisher) 2025
- 2.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 3Publisher website ·
- CiteScore 2026-06
- 3.6LetPub ·
- CiteScore (publisher) 2025
- 3.6Publisher website ·
- SJR 2026-06
- 0.4LetPub ·
- SJR (publisher) 2025
- 0.4Publisher website ·
- SNIP 2026-06
- 0.51LetPub ·
- SNIP (publisher) 2025
- 0.51Publisher website ·
- h-index
- 78LetPub ·
- h-index
- 126OpenAlex ·
- i10-index
- 4,226OpenAlex ·
- 2-year mean citedness
- 2.64OpenAlex ·
- Self-citation rate
- 7.7%LetPub ·
- Share of gold OA articles
- 2.37%LetPub ·
Volume
- Articles per year
- 163LetPub ·
- Downloads per year (publisher)
- 205,000Publisher website ·
Articles by year OpenAlex count · 7,579 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 116 | 5 | 43 |
| 2025 | 167 | 14 | 466 |
| 2024 | 94 | 7 | 485 |
| 2023 | 81 | 9 | 625 |
| 2022 | 69 | 8 | 702 |
| 2021 | 164 | 27 | 2,352 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
110 daysMedian, submission to acceptance · P25–P75 82 days – 175 days
- Acceptance to online
- median 14 days (102 articles)
- Submission to online
- median 127 days
- Sample
- 102 articles with submission and acceptance dates (306 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
- Acceptance rate (publisher)
- 27%Publisher website ·
- Submission to first decision
- 16 daysPublisher website ·
- First decision after review
- 55 daysPublisher website ·
- Acceptance to publication
- 17 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted9
- data notesTimely critical review papers within the journal scope are also welcomed, alongside data notes, letters to the editor, rapid communications and method articles.Length not stated
- letters to the editorTimely critical review papers within the journal scope are also welcomed, alongside data notes, letters to the editor, rapid communications and method articles.Length not stated
- methodMethod | Published online: 11 Sep 2026Length not stated
- method articlesTimely critical review papers within the journal scope are also welcomed, alongside data notes, letters to the editor, rapid communications and method articles.Length not stated
- rapid communicationsTimely critical review papers within the journal scope are also welcomed, alongside data notes, letters to the editor, rapid communications and method articles.Length not stated
- research articleResearch Article | Published online: 10 Sep 2026Length not stated
- research papersResearch papers must be hypothesis driven and emphasize innovative breakthrough topics.Length not stated
- review articleReview Article | Published online: 11 Sep 2026Length not stated
- review papersTimely critical review papers within the journal scope are also welcomed, alongside data notes, letters to the editor, rapid communications and method articles.Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Gold open access option Model summary
Drug Development and Industrial Pharmacy is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the di…
Source ↗Publisher website ·- Peer review
Single-anonymous peer review Model summary
All articles received by the journal will be subject to single-anonymous peer review.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- ISSN
- 0363-9045
- Electronic ISSN
- 1520-5762
- Latest issue on the website
- Volume 52, Issue 9 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Drug Development and Industrial Pharmacy
What CAS zone is Drug Development and Industrial Pharmacy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Drug Development and Industrial Pharmacy is in Zone 4 of Medicine, and in Zone 4 of the minor category Chemistry, Medicinal / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Drug Development and Industrial Pharmacy?
The latest impact factor listed by LetPub is 2.56; CiteScore 3.6, h-index 126.
How long does peer review take at Drug Development and Industrial Pharmacy?
Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 110 days (interquartile range 82–175 days); authors report an average review time of about 3 months; the community-reported acceptance is “about 75%”; the journal's website gives an acceptance rate of 27%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Drug Development and Industrial Pharmacy based?
Of the 42 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United States (17), United Kingdom (3) and Italy (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Drug Development and Industrial Pharmacy?
According to LetPub and DOAJ records, Drug Development and Industrial Pharmacy is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, Embase and CAS; that list has not been checked against each database.
Is Drug Development and Industrial Pharmacy open access, and what is the APC?
Drug Development and Industrial Pharmacy is a subscription journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .